Consequently, targeting EGFR with mAbs or tyrosine kinase inhibitors (TKI) has been established in cancer therapy in e.g. NSCLC, colorectal cancer, head and neck cancer, or pancreatic cancer but therapy resistance occurs frequently and compromises outcome (19). Here, EGFR is linked to familial pancreatic carcinoma.